201 related articles for article (PubMed ID: 10463052)
1. Evaluating reference-based pricing: initial findings and prospects.
Narine L; Senathirajah M; Smith T
CMAJ; 1999 Aug; 161(3):286-8. PubMed ID: 10463052
[TBL] [Abstract][Full Text] [Related]
2. Evaluating the impact of reference-based pricing.
Grootendorst P; Holbrook A
CMAJ; 1999 Aug; 161(3):273-4. PubMed ID: 10463048
[No Abstract] [Full Text] [Related]
3. Clinical and economic consequences of reference pricing for dihydropyridine calcium channel blockers.
Schneeweiss S; Soumerai SB; Maclure M; Dormuth C; Walker AM; Glynn RJ
Clin Pharmacol Ther; 2003 Oct; 74(4):388-400. PubMed ID: 14534526
[TBL] [Abstract][Full Text] [Related]
4. Impact of reference-based pricing for angiotensin-converting enzyme inhibitors on drug utilization.
Schneeweiss S; Soumerai SB; Glynn RJ; Maclure M; Dormuth C; Walker AM
CMAJ; 2002 Mar; 166(6):737-45. PubMed ID: 11944760
[TBL] [Abstract][Full Text] [Related]
5. Impact of reference-based pricing of nitrates on the use and costs of anti-anginal drugs.
Grootendorst PV; Dolovich LR; O'Brien BJ; Holbrook AM; Levy AR
CMAJ; 2001 Oct; 165(8):1011-9. PubMed ID: 11699696
[TBL] [Abstract][Full Text] [Related]
6. The impact of reference-pricing systems in Europe: a literature review and case studies.
Dylst P; Vulto A; Simoens S
Expert Rev Pharmacoecon Outcomes Res; 2011 Dec; 11(6):729-37. PubMed ID: 22098289
[TBL] [Abstract][Full Text] [Related]
7. Impact of reference-based pricing for histamine-2 receptor antagonists and restricted access for proton pump inhibitors in British Columbia.
Marshall JK; Grootendorst PV; O'Brien BJ; Dolovich LR; Holbrook AM; Levy AR
CMAJ; 2002 Jun; 166(13):1655-62. PubMed ID: 12126319
[TBL] [Abstract][Full Text] [Related]
8. Reference-based pricing: will other provinces follow the BC lead?
Mullens A
CMAJ; 1998 Jan; 158(2):239-41. PubMed ID: 9469150
[TBL] [Abstract][Full Text] [Related]
9. Reference-based pricing in British Columbia: implications for cardiologists--an analysis.
Boulet AP; Tessier G
Can J Cardiol; 1997 Jan; 13(1):46-51. PubMed ID: 9039064
[TBL] [Abstract][Full Text] [Related]
10. Why is calling an ACE an ACE so controversial? Evaluating reference-based pricing in British Columbia.
Anis A
CMAJ; 2002 Mar; 166(6):763-4. PubMed ID: 11944763
[No Abstract] [Full Text] [Related]
11. Seniors' prescription drug cost inflation and cost containment: evidence from British Columbia.
Morgan SG; Agnew JD; Barer ML
Health Policy; 2004 Jun; 68(3):299-307. PubMed ID: 15113641
[TBL] [Abstract][Full Text] [Related]
12. Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies.
Aaserud M; Dahlgren AT; Kösters JP; Oxman AD; Ramsay C; Sturm H
Cochrane Database Syst Rev; 2006 Apr; (2):CD005979. PubMed ID: 16625648
[TBL] [Abstract][Full Text] [Related]
13. Do policy changes in the pharmaceutical reimbursement schedule affect drug expenditures? Interrupted time series analysis of cost, volume and cost per volume trends in Sweden 1986-2002.
Andersson K; Petzold MG; Sonesson C; Lönnroth K; Carlsten A
Health Policy; 2006 Dec; 79(2-3):231-43. PubMed ID: 16473436
[TBL] [Abstract][Full Text] [Related]
14. Trends in cardiovascular drug utilization and drug expenditures in Canada between 1996 and 2001.
Jackevicius CA; Tu K; Filate WA; Brien SE; Tu JV;
Can J Cardiol; 2003 Nov; 19(12):1359-66. PubMed ID: 14631469
[TBL] [Abstract][Full Text] [Related]
15. Opportunity lost: a frontline view of reference-based pricing.
Woollard RF
CMAJ; 1996 Apr; 154(8):1185-8. PubMed ID: 8612254
[TBL] [Abstract][Full Text] [Related]
16. Comparative approaches to pharmaceutical price regulation in the European Union.
Mrazek MF
Croat Med J; 2002 Aug; 43(4):453-61. PubMed ID: 12187524
[TBL] [Abstract][Full Text] [Related]
17. Pharmaceutical policies in Canada: another example of federal-provincial discord.
Anis AH
CMAJ; 2000 Feb; 162(4):523-6. PubMed ID: 10701389
[TBL] [Abstract][Full Text] [Related]
18. Does therapeutic reference pricing always result in cost-containment? The Hungarian evidence.
Kaló Z; Muszbek N; Bodrogi J; Bidló J
Health Policy; 2007 Mar; 80(3):402-12. PubMed ID: 16730848
[TBL] [Abstract][Full Text] [Related]
19. [Evaluation of prescription practices and of the rational use of medicines in Niger].
Mallet HP; Njikam A; Scouflaire SM
Sante; 2001; 11(3):185-93. PubMed ID: 11641083
[TBL] [Abstract][Full Text] [Related]
20. Retail price regulation and innovation: reference pricing in the pharmaceutical industry.
Bardey D; Bommier A; Jullien B
J Health Econ; 2010 Mar; 29(2):303-16. PubMed ID: 20053474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
